Search Results

You are looking at 1 - 4 of 4 items for

  • Author: P Komminoth x
  • Refine by access: Content accessible to me x
Clear All Modify Search
A Perren
Search for other papers by A Perren in
Google Scholar
PubMed
Close
,
S Schmid
Search for other papers by S Schmid in
Google Scholar
PubMed
Close
,
T Locher
Search for other papers by T Locher in
Google Scholar
PubMed
Close
,
P Saremaslani
Search for other papers by P Saremaslani in
Google Scholar
PubMed
Close
,
C Bonvin
Search for other papers by C Bonvin in
Google Scholar
PubMed
Close
,
P U Heitz
Search for other papers by P U Heitz in
Google Scholar
PubMed
Close
, and
P Komminoth
Search for other papers by P Komminoth in
Google Scholar
PubMed
Close

The tumorigenesis of sporadic endocrine tumors is still not fully understood. Activating point mutations of the serine/threonine kinase gene BRAF located on 7q34 are found in a wide range of malignancies, with the highest frequency (66%) occurring in malignant melanomas. Melanomas are tumors of neural-crest-derived cells as are medullary thyroid carcinomas, pheochromocytomas and paragangliomas. BRAF has not been examined in endocrine tumors of the diffuse neuroendocrine system or of neural-crest-derived cells.

We examined 130 endocrine tumors of the pancreas, parathyroid gland, adrenal medulla, paraganglia, lung and gastrointestinal tract as well as follicular and c-cell-derived thyroid tumors. We found a high rate of V559E mutations in papillary thyroid carcinomas (47%), one V599E mutation in a well-differentiated gastric endocrine carcinoma (malignant carcinoid), but no activating BRAF mutations in all other endocrine tumors examined. These results point towards different pathways in tumorigenesis of endocrine tumors of various localizations and only rare involvement of the MAP kinase (MAPK) pathway in a subset of malignant neuroendocrine tumors.

Free access
M Montani
Search for other papers by M Montani in
Google Scholar
PubMed
Close
,
A M Schmitt
Search for other papers by A M Schmitt in
Google Scholar
PubMed
Close
,
S Schmid
Search for other papers by S Schmid in
Google Scholar
PubMed
Close
,
T Locher
Search for other papers by T Locher in
Google Scholar
PubMed
Close
,
P Saremaslani
Search for other papers by P Saremaslani in
Google Scholar
PubMed
Close
,
P U Heitz
Search for other papers by P U Heitz in
Google Scholar
PubMed
Close
,
P Komminoth
Search for other papers by P Komminoth in
Google Scholar
PubMed
Close
, and
A Perren
Search for other papers by A Perren in
Google Scholar
PubMed
Close

Germline mutations of the three succinate dehydrogenase subunits SDHB, SDHC and SDHD have recently been associated with familial pheochromocytoma and paraganglioma. Several reasons make these genes candidate tumor suppressor genes for medullary thyroid carcinoma (MTC): (1) SDHB lies on chromosome 1p, the region known to be deleted most frequently in MTC, (2) MTCs develop from neural crest-derived cells, as do pheochromocytomas and paragangliomas and (3) patients with germline mutations of the Ret-protooncogene develop MTCs as well as pheochromocytomas, indicating a relationship of these tumors on a genetic level. Therefore, we attempted to determine whether the tumor suppressor genes SDHB, SDHC and SDHD are involved in sporadic and familial MTC. Somatic mutations of the SDH subunits were absent in all 35 investigated MTCs. Loss of heterozygosity was found in 27% (SDHB) and 4% (SDHD) respectively. While the frequency of non-coding, intronic polymorphisms did not differ in MTC patients compared with a control population, an accumulation of amino-acid coding polymorphisms (S163P in SDHB as well as G12S and H50R in SDHD) was found among MTC patients especially patients with familial tumors, suggesting a functional connection of coding SDH polymorphisms to activating Ret mutations.

Free access
A M Schmitt
Search for other papers by A M Schmitt in
Google Scholar
PubMed
Close
,
S Schmid
Search for other papers by S Schmid in
Google Scholar
PubMed
Close
,
T Rudolph
Search for other papers by T Rudolph in
Google Scholar
PubMed
Close
,
M Anlauf Department of Pathology, Institute of Pathology, Department of Gastroenterology, Department of Pathology, Department of Pathology, Institute of Pathology, Institute of Surgical Pathology, Zurich, Switzerland

Search for other papers by M Anlauf in
Google Scholar
PubMed
Close
,
C Prinz Department of Pathology, Institute of Pathology, Department of Gastroenterology, Department of Pathology, Department of Pathology, Institute of Pathology, Institute of Surgical Pathology, Zurich, Switzerland

Search for other papers by C Prinz in
Google Scholar
PubMed
Close
,
G Klöppel Department of Pathology, Institute of Pathology, Department of Gastroenterology, Department of Pathology, Department of Pathology, Institute of Pathology, Institute of Surgical Pathology, Zurich, Switzerland

Search for other papers by G Klöppel in
Google Scholar
PubMed
Close
,
H Moch
Search for other papers by H Moch in
Google Scholar
PubMed
Close
,
P U Heitz
Search for other papers by P U Heitz in
Google Scholar
PubMed
Close
,
P Komminoth Department of Pathology, Institute of Pathology, Department of Gastroenterology, Department of Pathology, Department of Pathology, Institute of Pathology, Institute of Surgical Pathology, Zurich, Switzerland

Search for other papers by P Komminoth in
Google Scholar
PubMed
Close
, and
A Perren Department of Pathology, Institute of Pathology, Department of Gastroenterology, Department of Pathology, Department of Pathology, Institute of Pathology, Institute of Surgical Pathology, Zurich, Switzerland
Department of Pathology, Institute of Pathology, Department of Gastroenterology, Department of Pathology, Department of Pathology, Institute of Pathology, Institute of Surgical Pathology, Zurich, Switzerland

Search for other papers by A Perren in
Google Scholar
PubMed
Close

A small subset of familial pancreatic endocrine tumors (PET) arises in patients with von Hippel–Lindau syndrome and these tumors may have an adverse outcome compared to other familial PET. Sporadic PET rarely harbors somatic VHL mutations, but the chromosomal location of the VHL gene is frequently deleted in sporadic PET. A subset of sporadic PET shows active hypoxia signals on mRNA and protein level. To identify the frequency of functionally relevant VHL inactivation in sporadic PET and to examine a possible prognostic significance we correlated epigenetic and genetic VHL alterations with hypoxia signals. VHL mutations were absent in all 37 PETs examined. In 2 out of 35 informative PET (6%) methylation of the VHL promoter region was detected and VHL deletion by fluorescence in situ hybridization was found in 14 out of 79 PET (18%). Hypoxia inducible factor 1α (HIF1-α), carbonic anhydrase 9 (CA-9), and glucose transporter 1 (GLUT-1) protein was expressed in 19, 27, and 30% of the 152 PETs examined. Protein expression of the HIF1-α downstream target CA-9 correlated significantly with the expression of CA-9 RNA (P<0.001), VHL RNA (P<0.05), and VHL deletion (P<0.001) as well as with HIF1-α (P<0.005) and GLUT-1 immunohistochemistry (P<0.001). These PET with VHL alterations and signs of hypoxia signalling were characterized by a significantly shortened disease-free survival. We conclude that VHL gene impairment by promoter methylation and VHL deletion in nearly 25% of PET leads to the activation of the HIF-pathway. Our data suggest that VHL inactivation and consecutive hypoxia signals may be a mechanism for the development of sporadic PET with an adverse outcome.

Free access
Y M H Jonkers
Search for other papers by Y M H Jonkers in
Google Scholar
PubMed
Close
,
S M H Claessen
Search for other papers by S M H Claessen in
Google Scholar
PubMed
Close
,
A Perren
Search for other papers by A Perren in
Google Scholar
PubMed
Close
,
S Schmid
Search for other papers by S Schmid in
Google Scholar
PubMed
Close
,
P Komminoth
Search for other papers by P Komminoth in
Google Scholar
PubMed
Close
,
A A Verhofstad
Search for other papers by A A Verhofstad in
Google Scholar
PubMed
Close
,
L J Hofland
Search for other papers by L J Hofland in
Google Scholar
PubMed
Close
,
R R de Krijger
Search for other papers by R R de Krijger in
Google Scholar
PubMed
Close
,
P J Slootweg
Search for other papers by P J Slootweg in
Google Scholar
PubMed
Close
,
F C S Ramaekers
Search for other papers by F C S Ramaekers in
Google Scholar
PubMed
Close
, and
E-J M Speel
Search for other papers by E-J M Speel in
Google Scholar
PubMed
Close

Endocrine pancreatic tumors (EPTs) comprise a highly heterogeneous group of tumors with different clinical behavior and genetic makeup. Insulinomas represent the predominant syndromic subtype of EPTs. The metastatic potential of insulinomas can frequently not be predicted using histopathological criteria, and also molecular markers indicating malignant progression are unreliable because of the small number of cases per subtype studied so far. For the identification of reliable indicators of metastatic disease, we investigated 62 sporadic insulinomas (44 benign and 18 tumors with metastases) by means of comparative genomic hybridization (CGH). In addition, the role of MEN1 (multiple endocrine neoplasia type 1) gene mutations was determined to assess specific chromosomal alterations associated with dysfunction of this endocrine tumor-related tumor suppressor gene. Only one case with a somatic MEN1 mutation was identified (1527del7bp), indicating that the MEN1 gene plays a minor pathogenic role in sporadic insulinomas. CGH analysis revealed that the total number of aberrations per tumor differs strongly between the benign and the malignant group (4.2 vs 14.1; P<0.0001). Furthermore, chromosome 9q gain was found to be the most frequent aberration in both benign and malignant insulinomas, whereas chromosome 6q losses and 12q, 14q and 17pq gains are strongly associated with metastatic disease. Our study shows that chromosomal instability, as defined by ≥5 gains together with ≥5 losses, or total number of gains and losses ≥8, rather than parameters such as tumor size and proliferation index, is the most powerful indicator for the development of metastatic disease in patients with sporadic insulinoma.

Free access